Information Provided By:
Fly News Breaks for January 19, 2016
SRPT
Jan 19, 2016 | 07:03 EDT
As noted earlier, RBC Capital downgraded Sarepta to Sector Perform from Outperform. The firm believes that the negative opinions and conclusions regarding eteplirsen expressed in the FDA briefing documents will be difficult to combat. Target to $15 from $62.
News For SRPT From the Last 2 Days
There are no results for your query SRPT